Clinical Trials
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development
Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will be discontinued and resources will be reallocated to other compounds in the oncology pipeline. The decision was made after interim results from a Phase...
Clinical Trials
Genentech announced the result of Phase II clinical trail of RG7204
Genentech, Inc., a member of the Roche Group announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half...
Clinical Trials
Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical Development
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur’s dengue vaccine, the world’s most clinically advanced dengue vaccine candidate1,2, entered its first phase 3 clinical study...
Clinical Trials
Roche reports promising Phase II results with new targeted approach in advanced melanoma
Roche announced results from a Phase II clinical study of RG7204 PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors. ...
Clinical Trials
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML). Although the study did not...
Clinical Trials
Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill combination that delivers powerful and consistent blood pressure reductions
Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine...
Clinical Trials
Amgen announced that results from the PRIME ‘203’ and ‘181’ pivotal Phase 3 trials
Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read